X0206 3 2024-04-01 0 0001368514 ADMA BIOLOGICS, INC. ADMA 0002017423 Kestenberg-Messina Kaitlin M. C/O ADMA BIOLOGICS, INC. 5800 PARK OF COMMERCE BLVD. NW, BOCA RATON FL 33487 true COO and SVP, Compliance Common Stock 114275 D Restricted Stock Units 0 Common Stock 5000 D Restricted Stock Units 0 Common Stock 25000 D Restricted Stock Units 0 Common Stock 20000 D Restricted Stock Units 0 Common Stock 71250 D Restricted Stock Units 0 Common Stock 30000 D Stock Option (Right to Buy) 10.8 2025-01-30 Common Stock 5000 D Stock Option (Right to Buy) 8.98 2025-07-30 Common Stock 2500 D Stock Option (Right to Buy) 5 2027-02-14 Common Stock 5000 D Stock Option (Right to Buy) 4.72 2028-05-03 Common Stock 5000 D Stock Option (Right to Buy) 5.94 2028-10-09 Common Stock 6650 D Stock Option (Right to Buy) 4.31 2029-06-05 Common Stock 1563 D Stock Option (Right to Buy) 4.31 2029-06-05 Common Stock 937 D Stock Option (Right to Buy) 2.59 2030-03-10 Common Stock 20876 D Stock Option (Right to Buy) 2.83 2030-08-19 Common Stock 13334 D Stock Option (Right to Buy) 2.35 2031-02-25 Common Stock 30000 D Stock Option (Right to Buy) 1.55 2031-07-19 Common Stock 10000 D Includes 114,275 shares acquired pursuant to the vesting of restricted stock units ("RSUs"). On February 25, 2021, the Company granted the reporting person 20,000 RSUs, 5,000 of which are currently unvested, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. On September 28, 2021, the Company granted the reporting person 100,000 RSUs, 25,000 of which are currently unvested, with 50% vesting on December 31, 2022 and the remaining vesting quarterly from March 31, 2023 to December 31, 2024, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. On March 7, 2022, the Company granted the reporting person 40,000 RSUs, 20,000 of which are currently unvested, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. On March 6, 2023, the Company granted the reporting person 95,000 RSUs, 71,250 of which are currently unvested, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. On July 24, 2023, the Company granted the reporting person 30,000 RSUs, all of which remain unvested, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. The incentive stock options were granted to the reporting person on January 30, 2015, which are fully vested in accordance with the Amended and Restated ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan (the "Plan"). The incentive stock options were granted to the reporting person on July 30, 2015, which are fully vested in accordance with the Plan. The incentive stock options were granted to the reporting person on February 14, 2017, which are fully vested in accordance with the Plan. The incentive stock options were granted to the reporting person on May 3, 2018, which are fully vested in accordance with the Plan. The incentive stock options were granted to the reporting person on October 9, 2018, which are fully vested in accordance with the Plan. The incentive stock options were granted to the reporting person on June 5, 2019, which are fully vested in accordance with the Plan. The non-qualified stock options were granted to the reporting person on June 5, 2019, which are fully vested in accordance with the Plan. The incentive stock options were granted to the reporting person on March 10, 2020, which are fully vested in accordance with the Plan. The incentive stock options were granted to the reporting person on August 19, 2020, 2,084 of which are currently unvested. The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, subject to the reporting person's continued service as of the applicable vesting date. The incentive stock options were granted to the reporting person on February 25, 2021, 6,875 of which are currently unvested. The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, subject to the reporting person's continued service as of the applicable vesting date. The incentive stock options were granted to the reporting person on July 19, 2021, 3,334 of which are currently unvested. The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, subject to the reporting person's continued service as of the applicable vesting date. Exhibit 24 - Power of Attorney /s/ Kaitlin M. Kestenberg-Messina, by Adam S. Grossman as attorney-in-fact 2024-04-02